ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced, for the first time, data from its Phase 2 trial of Iclusig® (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The initial data show that ponatinib has anti-tumor activity in patients with advanced GIST, particularly in patients with KIT exon 11 mutations, after failure of at least one prior tyrosine kinase inhibitor (TKI). The primary endpoint for the trial, clinical benefit rate (CBR) at 16 weeks for patients with KIT exon 11 mutations, was 50 percent, with a median follow-up of six months. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 1.89%. On last trading day company shares ended up $6.46. Analysts mean target price for the company is $9.47. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -10.23%.
SIGA Technologies (NASDAQ:SIGA) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a note issued to investors on Monday, StockRatingsNetwork. SIGA Technologies, Inc. (NASDAQ:SIGA) shares fell -3.26% in last trading session and ended the day on $2.67. SIGA return on assets is -10.40%.SIGA Technologies, Inc. (NASDAQ:SIGA) quarterly performance is -16.82%.
International Isotopes Inc. (OTCBB:INIS) on 20 may announces the financial results for fiscal year ended December 31, 2013. The Company reports a 10% decrease in revenue, however, most business segments continue to show major improvement in net profit performance for the year.
Total revenue in 2013 was approximately $6.8 million compared to approximately $7.6 million in 2012, which represents a decrease of approximately 10%. International Isotopes Inc. (OTCBB:INIS) shares moved up 15.78% in last trading session and was closed at $0.0521, while trading in range of $0.04 – $0.05.
Athersys, Inc.’s (NASDAQ:ATHX) on 14 may announced, first quarter 2014 net loss of 15 cents per share was wider than the Zacks Consensus Estimate of a loss of 9 cents. The company had suffered a loss of 18 cents per share in the year-ago quarter. Athersys, Inc. (NASDAQ:ATHX) ended the last trading day at $1.78. Company weekly volatility is calculated as 6.24% and price to cash ratio as 3.05.Athersys, Inc. (NASDAQ:ATHX) showed a positive weekly performance of 19.46%.
Advanced Cell Technology, Inc. (OTCMKTS:ACTC) announced on 8 may, Revenue was $39,468 for the three months ended March 31, 2014, which was a decrease of $48,313 or 55.0% compared to the three months ended March 31, 2013. The decrease is due to license agreements that expired in 2013. On last trading day company shares ended up $0.0625.